Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
Purohit, A
Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. [electronic resource] - Lung cancer (Amsterdam, Netherlands) Nov 1998 - 119-25 p. digital
Publication Type: Clinical Trial; Journal Article
0169-5002
10.1016/s0169-5002(98)00072-5 doi
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Cisplatin--administration & dosage
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Interferon alpha-2
Interferon-alpha--administration & dosage
Male
Mesothelioma--drug therapy
Middle Aged
Pleural Neoplasms--drug therapy
Recombinant Proteins
Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. [electronic resource] - Lung cancer (Amsterdam, Netherlands) Nov 1998 - 119-25 p. digital
Publication Type: Clinical Trial; Journal Article
0169-5002
10.1016/s0169-5002(98)00072-5 doi
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Cisplatin--administration & dosage
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Interferon alpha-2
Interferon-alpha--administration & dosage
Male
Mesothelioma--drug therapy
Middle Aged
Pleural Neoplasms--drug therapy
Recombinant Proteins